A brief history of novel drug discovery technologies.

Nat Rev Drug Discov

AGW BioStrategy, 55 West 26 Street, Suite 10D, New York, New York 10010, USA.

Published: April 2003

Laypersons, researchers and clinicians alike speak of the biotechnology revolution with excitement. Media coverage of new breakthroughs in medicine often have the public and the investment community on the edge of their seats, eager for the next blockbuster drug to cure everything from high cholesterol levels to cancer. In this perspective, we examine some of the more popularized and influential new technologies in drug discovery and assess their relative impact on the actual attainment of new therapeutics.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd1064DOI Listing

Publication Analysis

Top Keywords

drug discovery
8
history novel
4
novel drug
4
discovery technologies
4
technologies laypersons
4
laypersons researchers
4
researchers clinicians
4
clinicians alike
4
alike speak
4
speak biotechnology
4

Similar Publications

Multifunctional Mycobacterial Topoisomerases with Distinctive Features.

ACS Infect Dis

January 2025

Department of Microbiology and Cell Biology, Indian Institute of Science, C.V. Raman Avenue, Bangalore 560012, India.

Tuberculosis (TB) continues to be a major cause of death worldwide despite having an effective combinatorial therapeutic regimen and vaccine. Being one of the most successful human pathogens, retains the ability to adapt to diverse intracellular and extracellular environments encountered by it during infection, persistence, and transmission. Designing and developing new therapeutic strategies to counter the emergence of multidrug-resistant and extensively drug-resistant TB remains a major task.

View Article and Find Full Text PDF

The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors.

Cell Biol Toxicol

January 2025

Department of Ultrasound, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning, China.

Histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein), collectively known as p300/CBP due to shared sequence and functional synergy, catalyze histone H3K27 acetylation and consequently induce gene transcription. p300/CBP over-expression or over-activity activates the transcription of oncogenes, leading to cancer cell growth, resistance to apoptosis, tumor initiation and development. The discovery of small molecule inhibitors targeting p300/CBP histone acetyltransferase activity, bromodomains, dual inhibitors of p300/CBP and BRD4 bromodomains, as well as proteolysis-targeted-chimaera p300/CBP protein degraders, marks significant progress in cancer therapeutics.

View Article and Find Full Text PDF

Ergostane-type steroids from mushrooms of Pleurotus genus.

J Nat Med

January 2025

Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba, 274-8510, Japan.

Steroids are physiologically important compounds for animals, plants, and fungi, and they have significantly contributed to drug discovery for many years. Fungi mainly biosynthesize ergostane-type steroids such as ergosterol. However, after the basic skeleton is biosynthesized, chemical transformations can lead to the cleavage or rearrangement of the fundamental skeleton of steroids.

View Article and Find Full Text PDF

Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation.

Med Oncol

January 2025

Engineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.

Temozolomide (TMZ)-based chemotherapy is a primary regimen for melanoma patients who have failed targeted therapy or immunotherapy. However, the low response rate of TMZ-based chemotherapy challenges the patients' prognosis. BRAF mutation is the most frequently mutated site in melanoma.

View Article and Find Full Text PDF

Bladder cancer often recurs, necessitating innovative treatments to reduce recurrence. We investigated non-thermal plasma's potential as a novel anti-cancer therapy, focusing on plasma-activated solution (PAS), created by exposing saline to non-thermal plasma. Our study aims to elucidate the biological effects of PAS on bladder cancer cell lines in vitro, as well as the combination with mitomycin C (MMC), using clinically relevant settings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!